Ulcer

Human medicines European public assessment report (EPAR): Simponi, golimumab, Date of authorisation: 01/10/2009, Revision: 49, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Liver, Marketing, MP, Heart, MRI, INN, Risk, MTX, Pneumonia, Fungus, AZA, UC, Eating, Inflammation, Ankylosing spondylitis, Infection, Fungal infection, Diagnosis, Anatomy, Ulcer, Lymphoma, IIA, Skin, Vasculitis, Yeast, Psoriasis, ATC, Joint, Pain, Psoriatic arthritis, Syringe, Disease, Nose, Allergy, Lower respiratory tract infection, Nonsteroidal anti-inflammatory drug, Hepatitis B virus, Safety, Heart failure, CRP, Disorder, Rheumatoid arthritis, Sepsis, Magnetic resonance imaging, Leukemia, Patient, Medical Subject Headings, Walking, Immune system, Ulcerative colitis, International, Arthritis, Language, Blood, Hepatitis B, Medication package insert, Tuberculosis, Select, Medicine, Methotrexate, Azathioprine, TNF, X-ray, Mercaptopurine, European Medicines Agency, Spine, DMARD, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Simponi, golimumab, Date of authorisation: 01/10/2009, Revision: 49, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Simponi, golimumab, Date of authorisation: 01/10/2009, Revision: 49, Status: Authorised

Human medicines European public assessment report (EPAR): Hefiya, adalimumab, Date of authorisation: 26/07/2018, Revision: 15, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, MRI, INN, Risk, Contraindication, AZA, Axial spondyloarthritis, Tissue, Heart, Cancer, Inflammation, Red, Disease-modifying antirheumatic drug, Ankylosing spondylitis, Infection, Back pain, Anatomy, Ulcer, IIA, Skin, Hidradenitis suppurativa, Tuberculosis, Bone marrow, ATC, Joint, Crohn's disease, Hidradenitis, Pain, Psoriatic arthritis, Bleeding, Disease, Nose, Ageing, Blood, Safety, Heart failure, CRP, Rheumatoid arthritis, Patient, Medical Subject Headings, Immune system, Ulcerative colitis, International, HS, Lupus, Arthritis, Language, Mouth, Laboratory, Scar, Child, Select, Medicine, Methotrexate, Azathioprine, TNF, Headache, Swelling, Stevens–Johnson syndrome, European Medicines Agency, Spine, Abscess, Rash, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Hefiya, adalimumab, Date of authorisation: 26/07/2018, Revision: 15, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Hefiya, adalimumab, Date of authorisation: 26/07/2018, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Hyrimoz, adalimumab, Date of authorisation: 26/07/2018, Revision: 14, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, INN, Contraindication, AZA, Tissue, Heart, Cancer, Inflammation, Red, Ankylosing spondylitis, Infection, Back pain, Anatomy, Ulcer, IIA, Skin, Hidradenitis suppurativa, Tuberculosis, Bone marrow, Psoriasis, ATC, Joint, Crohn's disease, Hidradenitis, Pain, Psoriatic arthritis, Bleeding, Disease, Nose, Blood, Safety, Heart failure, Rheumatoid arthritis, Patient, Medical Subject Headings, Immune system, Ulcerative colitis, International, HS, Lupus, Arthritis, Language, Mouth, Laboratory, Scar, Child, Select, Medicine, Methotrexate, Azathioprine, TNF, Headache, Swelling, Stevens–Johnson syndrome, European Medicines Agency, Spine, Abscess, Rash, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Hyrimoz, adalimumab, Date of authorisation: 26/07/2018, Revision: 14, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Hyrimoz, adalimumab, Date of authorisation: 26/07/2018, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 24, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, Contraindication, INN, Risk, AZA, Nausea, Heart, Inflammation, Disease-modifying antirheumatic drug, Infection, Diagnosis, Risk management, Anatomy, Ulcer, IIA, CHMP, Skin, Sinusitis, ATC, Joint, Pain, Psoriatic arthritis, Drainage, European, Disease, Ageing, Human, Safety, Heart failure, Rheumatoid arthritis, Medical Subject Headings, Agency, European Commission, Immune system, Ulcerative colitis, ACR, International, Arthritis, Language, Blood, Ciclosporin, Viral, Tuberculosis, Select, Patient, Medicine, Methotrexate, Azathioprine, Common, Tumor necrosis factor, Allergy, PUVA, Glycine mollis, Headache, Abdominal pain, Ankylosing spondylitis, Spine, Chronic pain, Committee, DMARD, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 24, Status: Authorised

MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads

Retrieved on: 
Thursday, December 21, 2023
Phase, Mortality, Mouth ulcer, Ulcer, Debridement, Amputation, Effect, Granulation tissue

Results show that EscharEx not only effectively debrides wounds, but also reduces biofilm and bacterial load in both VLUs and DFUs.

Key Points: 
  • Results show that EscharEx not only effectively debrides wounds, but also reduces biofilm and bacterial load in both VLUs and DFUs.
  • 70% of the patients (7/10) that completed the study achieved complete debridement within a median time of 5.5 days.
  • An average reduction of 35% in wound size was achieved by the end of the 2-week follow-up period.
  • Together with the outcomes of our previous Phase II study results, this study furthers the understanding of the effects of EscharEx.

US Digestive Health Expands Access to Advanced Gastroenterology Care Through its Partnership with Southwest Gastroenterology Associates (SWGA)

Retrieved on: 
Tuesday, December 19, 2023
IBD, Partnership, Physician, Human, GERD, Hand, Freedom, Cancer, Knowledge, Health, Patient, Diagnosis, Gastroenterology, Ulcer, Nursing

EXTON, Pa., Dec. 19, 2023 (GLOBE NEWSWIRE) -- US Digestive Health (USDH), one of the largest gastroenterology practices in the United States, managed by US Digestive Health Management (USDHM), a management services organization created to expand access to high-quality, low-cost gastroenterology care, today announced the addition of Southwest Gastroenterology Associates (SWGA), further expanding its comprehensive gastroenterology care services in Pennsylvania.

Key Points: 
  • EXTON, Pa., Dec. 19, 2023 (GLOBE NEWSWIRE) -- US Digestive Health (USDH), one of the largest gastroenterology practices in the United States, managed by US Digestive Health Management (USDHM), a management services organization created to expand access to high-quality, low-cost gastroenterology care, today announced the addition of Southwest Gastroenterology Associates (SWGA), further expanding its comprehensive gastroenterology care services in Pennsylvania.
  • “Southwest Gastroenterology has established itself as a trusted provider of high-quality, compassionate digestive health services in the region by delivering personalized care for its patients,” said Jerry Tillinger, CEO of USDHM.
  • US Digestive Health remains dedicated to upholding its reputation as a leading provider of digestive health services in the Northeastern United States.
  • US Digestive Health Management works hand in hand with gastroenterology partner practices to meet the challenges inherent in the fast-changing healthcare landscape.

Merakris To Share Data from Fully Enrolled First Part of Two-Part Dermacyte® Liquid Clinical Trial

Retrieved on: 
Tuesday, December 5, 2023
Conference, FDA, Trial of the century, Research, Therapy, Vein, Clinical trial, GCP, Quality, Patent, Part, Good, Safety, Leg, Veterans' affairs, Ulcer, Skin, Pharmaceutical industry

The Research Tringle Park–headquartered biotechnology company plans to share its initial findings on December 6 at the Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference in Phoenix, AZ.

Key Points: 
  • The Research Tringle Park–headquartered biotechnology company plans to share its initial findings on December 6 at the Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference in Phoenix, AZ.
  • Part 1 of the clinical trial should be completed by the end of this year.
  • Merakris will discuss its interim data at a workshop on the first day of the four-day Desert Foot Conference.
  • Broderick said the company, which has filed 10 patent applications covering Dermacyte Liquid and its unique mode of action, plans to conduct more clinical studies in the future.

Spectral AI to Participate in Benchmark’s 12th Annual Discovery One-on-One Conference

Retrieved on: 
Thursday, November 30, 2023
Conference, MDAI, Government, FDA, Burn, CE, UKCA, Ulcer, 3D, DFU, Spectral, Artificial intelligence, Burns, Patient, Algorithm, History, Medical device

DALLAS, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in clinical wound care, today announced that it will participate in the Benchmark 12th Annual Discovery One-on-One Conference being held on December 7, 2023 in New York City.

Key Points: 
  • DALLAS, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in clinical wound care, today announced that it will participate in the Benchmark 12th Annual Discovery One-on-One Conference being held on December 7, 2023 in New York City.
  • Management will participate in 1x1 meetings throughout the day with institutional investors.
  • For more information on the Benchmark 12th Annual Discovery One-on-One Conference, or to schedule a one-on-one meeting, please contact your Benchmark representative or visit the Conference Website: Click here .
  • Together with previous contracts, this brings total U.S. Government awards to the Company since 2019 to more than $246.0 million.

Cinesteam Helps Manage Malodorous Smells from Leg Ulcers

Retrieved on: 
Tuesday, December 19, 2023
Quality of life, Cleveland Clinic, Mouth ulcer, Business, Pain, Embarrassment, Intense, Swelling, Patient, NHS, Bacteria, OTC, Leg, Ulcer

FORT LAUDERDALE, Fla., Dec. 19, 2023 /PRNewswire/ -- Leg ulcers are a common issue in America. Cleveland Clinic reports that as many as 4% of those over 65 years old have nonhealing wounds on their legs. Even when they are treated appropriately, leg ulcers can take weeks to go away. NHS adds that the condition can lead to pain, swelling, and itching. In addition, there can be what the publication refers to as "a foul-smelling discharge" that comes from the chronic wound. When a leg ulcer also becomes infected and generates odors, this can become overwhelming for a patient. That's where Cinesteam can make a difference.

Key Points: 
  • FORT LAUDERDALE, Fla., Dec. 19, 2023 /PRNewswire/ -- Leg ulcers are a common issue in America.
  • Even when they are treated appropriately, leg ulcers can take weeks to go away.
  • "Leg ulcers can easily become infected, and when that happens, infected leg ulcers can generate unpleasant smells," says Clémence Desjardin, Director of Operations and Business Development at Cemag Care.
  • However, Cinesteam dressings provide an additional layer of odor protection that can make it much easier for those managing leg ulcers to remain comfortable and socially engaged rather than isolated.

Cinesteam Incorporates Individuals Battling Chronic Illness Into the Holidays

Retrieved on: 
Tuesday, December 19, 2023
Holiday, Family, Travel, Motivation, Business, Friends, Embarrassment, Ulcer, Love, NerdWallet, Burns, Wound, OTC, Nursing

FORT LAUDERDALE, Fla., Dec. 19, 2023 /PRNewswire/ -- The holidays are a time traditionally spent with friends and family. NerdWallet reports that more than 130 million Americans plan on investing serious money in travel expenses this holiday. The motivation? To have quality time with those that they love. However, one group that will be conspicuously absent from many holiday gatherings this year is those who are dealing with chronic wounds that create significant malodors.

Key Points: 
  • Cinesteam Is Making It Possible for Them to Enjoy the Holidays With Others Again.
  • FORT LAUDERDALE, Fla., Dec. 19, 2023 /PRNewswire/ -- The holidays are a time traditionally spent with friends and family.
  • NerdWallet reports that more than 130 million Americans plan on investing serious money in travel expenses this holiday.
  • Desjardin is the Director of Operations and Business Development at Cemag Care and serves as the manager for Cinesteam Brand.